Non-Small Cell Lung Carcinoma Advanced Locally Curative treatment Amenable | Non-small cell lung cancer metastatic Curative treatment Amenable | TNM clinical staging
Item
diagnosis of locally advanced or metastatic (stage iii or iv at entry) non-small cell lung cancer (nsclc) that is not amenable to curative therapy.
boolean
C0007131 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C1517927 (UMLS CUI [1,3])
C1273390 (UMLS CUI [1,4])
C3900053 (UMLS CUI [1,5])
C0278987 (UMLS CUI [2,1])
C1273390 (UMLS CUI [2,2])
C3900053 (UMLS CUI [2,3])
C3258246 (UMLS CUI [3])
Prior Chemotherapy Platinum-Based Locally Advanced Malignant Neoplasm | Prior Chemotherapy Platinum-Based Metastatic Neoplasm | Neoadjuvant Chemotherapy | Chemotherapy, Adjuvant | Chemotherapy Additional Recurrence
Item
patients must have been previously treated with one platinum-containing chemotherapy regimen for locally advanced or metastatic disease. patients are also eligible if they have received one platinum-based chemotherapy regimen as neoadjuvant or adjuvant chemotherapy, but must have received an additional chemotherapy regimen upon recurrence.
boolean
C1514457 (UMLS CUI [1,1])
C1514162 (UMLS CUI [1,2])
C0677984 (UMLS CUI [1,3])
C1514457 (UMLS CUI [2,1])
C1514162 (UMLS CUI [2,2])
C2939420 (UMLS CUI [2,3])
C0600558 (UMLS CUI [3,1])
C0392920 (UMLS CUI [3,2])
C0085533 (UMLS CUI [4])
C0392920 (UMLS CUI [5,1])
C1524062 (UMLS CUI [5,2])
C2825055 (UMLS CUI [5,3])
cancer treatment Systemic Quantity
Item
no more than two prior systemic anti-cancer therapies will be allowed.
boolean
C0920425 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
prior radiation therapy Bone Marrow Percentage | prior radiation therapy Whole-Pelvis | prior radiation therapy Completed | Toxic effect Patient Recovered
Item
prior radiation therapy is allowed to less than 25% of the bone marrow. prior radiation to the whole pelvis is not allowed. prior radiotherapy must be completed at least 2 weeks before study enrollment, and the patient must have recovered from the acute toxic effects of the treatment prior to study enrollment.
boolean
C0279134 (UMLS CUI [1,1])
C0005953 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
C0279134 (UMLS CUI [2,1])
C3827467 (UMLS CUI [2,2])
C0279134 (UMLS CUI [3,1])
C0205197 (UMLS CUI [3,2])
C0600688 (UMLS CUI [4,1])
C0030705 (UMLS CUI [4,2])
C0521108 (UMLS CUI [4,3])
Pregnancy
Item
pregnancy.
boolean
C0032961 (UMLS CUI [1])
Breast Feeding
Item
breast-feeding.
boolean
C0006147 (UMLS CUI [1])
Second Primary Cancer
Item
second primary malignancy that is clinically detectable at the time of consideration for study enrollment.
boolean
C0751623 (UMLS CUI [1])
Aspirin Unable to discontinue Period | Non-Steroidal Anti-Inflammatory Agents Unable to discontinue Period
Item
inability to interrupt aspirin, or other nonsteroidal anti-inflammatory agents for a 5-day period.
boolean
C0004057 (UMLS CUI [1,1])
C1548265 (UMLS CUI [1,2])
C1948053 (UMLS CUI [1,3])
C0003211 (UMLS CUI [2,1])
C1548265 (UMLS CUI [2,2])
C1948053 (UMLS CUI [2,3])
Folate intake Unwilling | Vitamin B12 supplement Intake Unwilling
Item
inability or unwillingness to take folic acid or vitamin b12 supplementation.
boolean
C0564428 (UMLS CUI [1,1])
C0558080 (UMLS CUI [1,2])
C3661610 (UMLS CUI [2,1])
C1512806 (UMLS CUI [2,2])
C0558080 (UMLS CUI [2,3])